Just wondering if it is in big pharmas best interest to know earlier that a patient is developing DKD. If it means shorter treatment time using their drug, they might prefer their patients develop full blown DKD. Thinking that the money may come from GPs - where patients at risk of developing DVD (overweight etc.) are asked to take Promarker D. Thoughts?
Where to from here?, page-46
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.005(0.49%) |
Mkt cap ! $134.2M | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.06 | $1.00 | $134.2K | 131.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3987 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 4762 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |